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HMGB1: a novel protein that induced platelets
active and aggregation via Toll-like receptor-4,
NF-κB and cGMP dependent mechanisms
Xinyu Yang1, Haichao Wang2, Menmen Zhang3, Jin Liu1, Ben Lv1,2 and Fangping Chen1,3*
Abstract
Background: Thrombotic diseases are a group of prevalent and life-threatening diseases. Selective inhibition of
pathological thrombosis holds the key to treat variety of thrombotic diseases. The pathological thrombosis can be
induced by either tissue necrosis and deregulated inflammation. HMGB1, as an important proinflammatory cytokine
and a late mediator, also involves on thrombosis disease. However, the underlying mechanisms are not fully
understood.
Methods: Immunofluorescence, ELISA assay, Platelet Aggregation, Thromboelastogram (TEG) analyzes. Flow
cytometric analysis and Western blot analysis were used to investigated the role of HMGB1 in platelet aggregation
and obtained following observations.
Results: By doing so, we obtained the following observations: i) Highly purified HMGB1 recombinant protein
induces platelet aggregation and secretion in a dose-dependent manner in the presence of serum. ii) Low
concentration of extracellular HMGB1 could synergistically promote subthreshold concentration of collagen or
thrombin induced platelet aggregation. iii) Extracellular HMGB1 promoted platelet aggregation in a platelet-expressed
GPIIb/IIIa-dependent manner. iv) We proposed that extracellular HMGB1 seems to promote the phosphorylation of
GPIIb/IIIa and subsequent platelet aggregation via TLR4/NF-κB and cGMP pathway.
Conclusions: In this study, we provide evidence for the hypothesis that HMGB1 interact with platelet might play an
important role in the haemostasis and thrombotic diseases. Our research might be provide an interesting avenue for
the treatment of thrombotic diseases in the future.
Keywords: HMGB1, Platelet aggregation, Thrombosis
Background
Evidence from basic and clinical medicine had clearly
proven that there were complex interactions between
inflammation and thrombosis. The pathogenesis of
thrombosis remains complicated. Inflammation increases
immune cells or endothelial cell release of procoagulant
factors, such as cytokines, chemokines, adhesion mole-
cules were released, tissue factor expression, platelet and
endothelial activation [1], however, inflammation not
only leads to activation of coagulation, and vice versa
coagulation also considerably affects inflammatory ac-
tivity and even augments inflammation, at present,
the commonly accepted notion that inflammation and
hemastasis are coupled by common activation path-
way and feedback regulation system [2, 3], generally
speaking, inflammation including sterile and infection-
associated inflammation states, but the common fea-
tures of the two in the process of inflammation are
accompanied by cells necrotic and and immune cell
activation [3].
High mobility group box chromosomal protein 1
(HMGB1) was originally discovered as a chromatin-
binding protein that could bend DNA. Such bending
stabilizes nucleosome formation and regulates the expres-
sion of select genes upon recruitment by DNA binding
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proteins [4, 5]. Then, researchers discovered that extra-
cellular HMGB1 can be released from necrotic cells,
apoptotic cells or multiple immunocompetent cells and
displayed a broad spectrum of biological activities [6, 7],
importantly, extracellular HMGB1 play a critical role in
activation of the innate immune response, by functioning
as a chemokine facilitating movement of immune cells to
sites of infection, as well as in functioning as a damage-
associated molecular pattern (DAMP), activating other
immune cells to secrete proinflammatory cytokines, thus
promoting the immune response [8]. Recently, double-
stranded RNA-dependent protein kinase (PKR) identified
as a crucial regulator of inflammatory mediator HMGB1
released [9]. Present study clearly indicated that extracel-
lular HMGB1 transmembrane signaling pathways main
through Toll-like receptor (TLR)-4, TLR-2, and the recep-
tor of advanced glycation end products (RAGE) [10, 11].
Moreover, HMGB1, as an important proinflammatory
cytokine and a late mediator, also involves on thrombosis
disease. A growing number of studies suggest that a
potential role of HMGB1 in during thrombus develop-
ment. In recent years, our study for the first time pro-
vided evidence that extracellular HMGB1, potentially
through activation of transcription factors such as NF-κB,
enhanced tissue factor (TF) expression and activities in
vascular endothelial cells (ECs) and macrophages [12].
Moreover, another recent clinical study, doctors discoverd
circulating HMGB1 has been shown to be independently
associated with cardiac mortality in ST-segment elevation
myocardial infarction [13].
Here, we found that either the resting platelets
cytoplasm or the supernatant of activated platelets high
expression of HMGB1 protein. Platelets play a central
role in thrombosis, hemostasis, and inflammation. In
addition to their known role in hemostasis and throm-
bosis, platelets also as immune cells, that forms a bridge
between inflammation and thrombosis disease, play
proinflammatory and procoagulant in vivo [14]. In
addition, platelet also expression function TLR2, TLR4
and RAGE which implicated in the regulation of plate-
let adhesion, aggregation [15, 16]. For instance, recently
reported that histone, which similar to HMGB1 protein
as DAMP, could induce platelet aggregation and throm-
bin generation through platelet TLR2 and TLR4 [17].
Platelet activation and aggregation is essential for normal
hemostasis and also plays a important role in thrombosis.
In the past, although some researchers speculated that
HMGB1 protein capable of activating platelets [18], but
the mechanism was previously unclear. For the first time,
we provided evidence that HMGB1 could direct induced
platelets aggregation and secretion, moreover, extracel-
lular HMGB1 could significantly promote other agonists-
induced platelets aggregation. Furthermore, extracellu-
lar HMGB1 interact with platelets mainly depended on
TLR4/NF-κB and cGMP-dependent pathway. Taken
together, our experimental data suggest that HMGB1
protein this potent procoagulant function may contrib-
ute to pathogenesis of thrombosis.
Method
Recominant HMGB1 (rHMGB1) protein was expressed in
Escherichia coli, and purified to homogeneity as described
previously [19]. Purified HMGB1 was tested for endotoxin
content by the chromogenic Limulus amebocyte lysate
assay (Endochrome, Charles River, Wilmington, MA,
USA), and contained < 500 pg endotoxin per microgram
of rHMGB1. Blocking mAbs against human TLR2 (clone
T2.5), TLR4 (HTA125), and isotype control (IgG2a, from
eBioscience); mouse anti-human RAGE (R&D Systems,
Catalog Number: MAB11451; 20 μg/ml), PE/FITC/Percp
labeled anti-human IgG1, FITC-labeled anti-human PAC-
1, PE-labeled anti-human CD62P, Percp-labeled anti-
human CD61, FITC-anti-human labeled CD42b, PE-
labeled anti-human CD41 (all from BD, USA), collagen
(T-7009,100UN) and thrombin (Sigma), Ristocetin (Absin
China), Rabbit polyclonal anti-HMGB1 antibodies (R&D
Systems), human HMGB1 enzyme-linked immunosorbent
assay (ELISA) kit was purchased from Shino-Test Corpor-
ation (Tokyo, Japan). Proteinase K (500 μg/ml Sigma-
Aldrich). Sodium nitroprusside (SNP; 100 μM, Sigma,
USA).
Patients and samples
Blood samples were obtained from five healthy donors
and the patient with Glanzmann thrombasthenia (GT)
is a 40-year-old woman, the detailed data about la-
boratory molecular biological diagnostic had published
in Blood [20], the institutional ethics committee of the
third Xiangya hospital of central south university ap-
proved this study, all patients and healthy donors gave
their informed consent in accordance with the declar-
ation of Helsinki. Blood sampling, PRP preparation and
platelet isolation, all peripheral venous blood was col-
lected from patients or healthy human volunteers by
puncture with a 19-gauge needle, Storage tube contain
3.8 % trisodium citrate (9:1 blood-to-citrate ratio, BD
Vacutainer™ tubes). PRP preparation and platelet isola-
tion processed as described previously [17]. PRP was
centrifuged at 1000 rpm for 10 min at at room tem-
perature (RT) in the presence of 1 μg ml-1 PGE1 (Sigma-
Aldrich) and next 3000 rpm for 10 min then washed in
washing buffer (140 mM NaCl, 10 mM NaHCO3,
2.5 mM KCl, 0.5 Mm Na2 HPO4, 1 mM MgCl2, 22 mM
sodium citrate, 0.55 mM glucose, 0.35 % BSA, pH6.5). Fi-
nally, washed human platelets (WPs) were resuspended in
Tyrode’s buffer (Tyrode buffer composition was 10 mmol/L
of HEPES pH7.5, 140 mmol/L of NaCl, 2.7 mmol/L of KCl,
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0.2 mmol/L of Na2HPO4, 12 mmol/L of NaHCO3,
5.5 mmol/L of D-glucose, and 1 mmol/L of MgCl2).
Immunofluorescence
WPs were resuspended in Tyrode’s buffer, then platelets
of two groups were fixed with 1 % paraformaldehyde
and cytospined after by adding thrombin, the processed
platelets incubated overnight with rabbit polyclonal anti-
HMGB1 antibodies and Rabbit polyclonal anti-actin
antibodies. The washed platelets were incubated for 1.5 h
at RT with the secondary Ab Alexa Fluor 488 or 568
(Molecular Probes) at a dilution of 1:500 followed by 3
washes in PBS. Images of platelets were visualized by
fluorescent microscopy (Nikon), shutter and image ac-
quisition were controlled by MetaMorph software (MDS
Analytical Technologies).
ELISA assay
The addition or not addition of thrombin (0.2 U/ml) to
WPs, respectively measured protein of HMGB1 in the
supernatant and pellet after platelet activation, the rest
platelet as control. HMGB1 plasma concentrations were
measured using the HMGB1 ELISA Kit II according to
the manufacturer’s protocols. The lower limit of quanti-
fication for the assay was 0.2 ng/mL for HMGB1. Each
sample was run in duplicate and the mean concentration
was determined.
Platelet aggregation
Aggregation of platelets were finished in 30–40 min
when fresh blood from healthy volunter was collected,
the method was optically monitored in a Data 4-
chamber aggregometer (Chrono-Log Lumi-aggregomete)
at 37 °C, magnetic stick at a constant stirring rate of
1200 rpm, PRP was centrifuged at 1000 rpm for 10 min
at at RT, adjust the number of platelets (200–250 × 109/
mL) in WPs, Light ray transience through WPs is 100 %,
but through Tyrode’s buffer it is 0 % due to differing
optical density. WPs (200 μl) was poured into glass tubes
in the presence of a magnetic stick, platelet aggregation
was determined by adding 50 μl of HMGB1 or other
agonists, including Thrombin (0.2 unit/ml), Collagen
0.3 μg/ml, Ristocetin (RIS 1.25 mg/ml), Albumin (μg/ml)
was set as negative control.
Thromboelastogram (TEG) analyzes
A whole blood kaolin-activated thromboelastogram (TEG)
analyses was run in a CFMSTM thromboelastography(-
China), TEG experiment with CFMSTM thromboelasto-
grap General Cup Test Kit (viscosity measuring). The basic
TEG parameters include reaction time R, angle of alpha (α)
and Maximum Amplitude (MA). With whole blood 2 ml
from health donors storaged in tube contained 3.8 % triso-
dium citrate (9:1 blood-to-citrate ratio, BD Vacutainer™
tubes). take 1 ml of whole blood to the first reagent reacting
vessel (contain kaolin clay) of the kit, a final concentration
of 1 μg/ml HMGB1 protein were added or not added to
some vessels, very slowly with sufficient mixing, waiting for
5 min, then, adding 20 μl CaCl2 (the second reagent react-
ing vessel) to the bottom of reaction cups, At the time the
reaction was started, 320 μL of citrated whole blood was
added to the cup, and the recording was initiated. All TEG
analyzes were performed within one hour after sample
collection.
Flow cytometric analysis
Platelets in Tyrode buffer were incubated with HMGB1
for 10 min at 37 °C and then in the presence of
2.5 mmol/L of CaCl2. Albumin (60 μg/ml) as control,
next, For P-selectin and PAC-1 evaluation, platelets
were diluted in HBS and fixed with adding paraformal-
dehyde (final concentration of 1 %) in at 37 °C for
5 min; afterward, they were washed and incubated in
HBS with 1 % BSA containing FITC-labeled PAC-1 or
PE-labeled CD62P or Percp-labeled CD61 for 30 min,
in some experiments, platelets were pre-incubated with
anti-TLR2 mAbs, anti-TLR4 mAbs, anti-human RAGE
mAbs or IgG2a (50 μg/mL) for 20 min at RT; then
washed again and resuspended in HBS with 1 % BSA,
For analysis patients with GT, platelets were washed
and incubated in HBS with 1 % BSA containing Percp-
labeled CD61 or FITC-labeled CD42b or PE-labeled
CD41a, PE/FITC/Percp labeled anti-human IgG1 as iso-
type control antibody, expression was analyzed using a
FACSCalibur flow cytometer (BD Biosciences).
Measurement of platelet cGMP, cAMP levels
WPs pre-incubated with or without blocking mAbs anti-
TLR2, anti-TLR4, anti-human RAGE or IgG2a mAbs
(60 μg/mL) for 10 min at 37 °C respectively. HMGB1
was added to WPs that were stirred at 37 °C in a platelet
aggregometer for 5 min. and the reaction stopped by
addition of ice-cold 12 % (w/v) trichloroacetic acid.
Samples were mixed and centrifuged at 2000 g for
15 min at 4 °C and the supernatant was extracted four
times with water-saturated diethyl ether. The samples
were lyophilized (≤-20 °C) and concentration determined
using a cGMP, cAMP enzyme immunoassay kit from
Amersham Biosciences. Results are expressed as mean ±
SD.
Western blot analysis
WPs lysates (109 cells/mL) were prepared in loading buffer
(62.5 mM Tris–HCl at pH 6.8, 25 % glycerol, 2 % SDS,
0.01 % bromophenol blue and 5 % 2-mercaptoethanol) in
the presence of a protease inhibitor cocktail containing
1 mM AEBSF, 2 μg/ml aprotinin, 1 μg/ml leupeptin. Equal
volume of platelet proteins were resolved by 12 % sodium
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dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The proteins were transferred to a PVDF mem-
brane (Millipore) by semidry transfer, Antibodies to human
HMGB1mAb (R&D Systems), and Actin(Cell Signaling).
Mouse anti-IκBα, rabbit anti-phospho IκBα were from
Abcam (UK).
Statistical evaluation
All data are presented as mean ± standard deviation
(SD). Statistical analysis was performed by the Student t-
test or ANOVA as appropriate. P < 0.05 was considered
to be statistically significant.
Result
Resting human platelets express cytoplasmic HMGB1,
activated platelet release of HMGB1
In our study, we discovered that HMGB1 protein was
high expressed in washed human platelets (WPs). Next,
we further confirmed HMGB1 protein were mainly lo-
cated in the intracellular when it in the resting state by
immunoblotting or ELISA test, rarely HMGB1 protein
exist in the plasm, the resting platelets in pellets contain
HMGB1 protein were 10.27 ± 1.01 ng/109 platelets, the
extracellular fluid of platelets contain HMGB1 protein
were only 0.19 ± 0.13 ng/109 platelets, however, when
added simultaneously with the platelet agonists throm-
bin (0.2 U/ml), thrombin-stimulated platelets contain
HMGB1 protein in pellets were changed to 2.39 ±
0.70 ng/109 platelets and extracellular HMGB1 protein
levels in the supernatant significantly increase to 7.86 ±
1.10 ng/109 platelets. Compared to resting platelets, the
level of HMGB1 protein both in pellets and in supernatant
had statistically significant difference after thrombin-
stimulated platelet (Fig. 1). The results are consistent
with other researcher previous finding [18]. The pur-
pose of releasing of the HMGB1 protein during plate-
let activation is still not clear, what kind of role it will
play in platelet activation is our next step focal point.
High conceration of rHMGB1 protein directly induce
platelet aggregation and low dose of rHMGB1 protein
potentiates other agnoists-induced platelet aggregation
activated platelets release of HMGB1 protein, which is
whether similar to thromboxane A2 (TXA2), ADP, or
Polyphosphates (Polyp) that were released from activa-
tion of platelets then involved in increasing platelet-self
activation or enhances blood clotting reactions.so we
first examined the effect of rHMGB1 protein on platelet
aggregation, test results were amazing and revealed that
stimulation of WPs with various levels of HMGB1
Fig. 1 Platelets express HMGB1. a Representative immunoblot of HMGB1 expressions in WPs (1 × 109/ml) from five different health donors,
Western blot analysis of extracts HMGB1 protein by HMGB1 polyclonal antibodies. b HMGB1 was assessed by ELISA in pellets and supernatant of
WPs that either resting or adding thrombin (0.2 U/ml). After WPs were activated, the concentration of HMGB1 in pellets or in the supernatant
signicantly different from the resting WPs group (n = 5, *P < 0.01). c WPs incubated with or without (negative controls) rabbit polyclonal-anti-HMGB1
(blue) in combination with rabbit-anti-Actin (red), respectively. Images under fluorescent microscopy, the results indicated that the resting
WPs high expression of HMGB1 protein
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protein (0 to 160 μg/ml) led to a concentration de-
pendent induction of platelet aggregation (Fig. 2a, b). A
few micrograms of (1–5 μg/ml) rHMGB1 protein alone
can not induce platelet aggregation, while as the protein
concentration increasing, compared to control group
(ALB), rHMGB1 protein (10 μg/ml) induce platelet
aggregation rate were 10.3 % ± 4.7 % (n = 5, P < 0.05),
because LPS stimulation also can induce platelet secre-
tion and promote aggregation. we wish to exclude the
possibility that contaminating LPS in the HMGB1
preparation (<500 pg LPS per microgram of HMGB1)
contributes to the observed increase platelet aggrega-
tion. Accordingly, an effective inhibitor of LPS, poly-
myxin B (PMB), was employed in parallel experiments.
when given at a low concentration (500 pg/ml), LPS
not direct induce platelet aggregation, LPS effect com-
pletely abrogated after rHMGB1 by co-incubation with
PMB (1 μg/ml). We found that rHMGB1 (40 μg/ml)-
induced platelet aggregation was not decreased by
PMB (Fig. 2c, d). in contrast, rHMGB1-induced platelet
aggregation generation was severely impaired in the
presence of the proteinase K (PK) which dissolves the
rHMGB1 proteins and destroy the native protein struc-
ture. When HMGB1 pre-incubated with PK (500 μg/ml)
then the platelet aggregation drop markedly from 47.4 % ±
5.2 % to 11.7 % ± 5.7 % (n = 5, P < 0.05). We acquired
the same result that treatment HMGB1 via rreversible
thermal denaturation that changed the protein high-
grade structure with high temperature cannot induce
platelet aggregation.
Hatada et al. from Japan reported that disseminated
intravascular coagulation (DIC) was associated with sig-
nificantly high plasma HMGB1 and the highest plasma
levels of HMGB1 can be achieved 16.58 ± 11.01 ng/ml in
non-survivors patients with organ failure [21]. Accord-
ingly this reports, we speculated that the highest plasma
levels of HMGB1 protein in local inflammation, necrotic
tissue or worn-out organs may achieve a few micro-
grams. now that low dose of HMGB1 protein (1 μg/ml)
which alone incapable of inducing platelet aggregation, it
Fig. 2 HMGB1 directly induces platelet aggregation, results are expressed as mean ± SE. The data shown here are representatives of at least five
experiments from different donor. a Various concentrations of HMGB1 protein induced platelet aggregation curves, albumin (ALB) is negative
control, (b). Record data are means the maximum platelet aggregation rate induced by HMGB1 (n = 5, *P < 0.05 vs. ALB group). c and d The
effects of PMB or proteinase K on HMGB1-induced platelet aggregation curves. HMGB1 (40 μg/ml) were pretreatmented with PMB (1 μg/ml) or
proteinase K (500 μg/ml PK) for 10 min at RT, or thermal denaturation of HMGB1 (TD) at 100 °C for 10 min respectively, rHMGB1-induced platelet
aggregation were obvious inhibited by PK or treatment of thermal denaturation, but not affected by PMB. (n = 5, *P > 0.05; **P < 0.05. vs
HMGB1 group)
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was unknown that low level of HMGB1 protein together
with other agonists whether had best cooperation effects.
Therefore, when adding simultaneously with subthresh-
old concentrations of agonists thrombin (0.2 U/ml) or
collagen (0.3 μg/ml), we discovered that HMGB1 in-
creased the maximum platelet aggregation rate induced
by subthreshold level of thrombin or collagen (Fig. 3a, b).
These results were further confirmed by thromboelasto-
gram (TEG) analyzes. when the whole blood were pre-
treatmented with HMGB1, the Maximum Amplitude
(MA) in TEG, which represents fibrin and platelet
aggregation, was significantly enhanced from 61.7 ±
6.8 mm to 75.6 ± 7.5 mm (n = 5, P < 0.05) (Fig. 3c, d).
Meanwhile, from the the result of TEG, we found that
the cloting reacting time (R min), which represents the
rate of initial fibrin formation and is related to plasma
clotting factors and circulating inhibitory activity, gotten
slightly extended but between of two have no statistical
differences (data not show). These result suggested that
HMGB1 incapable of initiating coagulation through
directly activate coagulation factor.
Measurement of ATP release and expression of P-selectin
Platelet secretion is critical in amplifying platelet activation
and in stabilizing thrombus. It is well established that
activation platelets secreted ATP from dense granules. In
addition, P-selectin which is a member of selectin family of
cell surface receptor and also known as platelet activa-
tion dependent granule external membrane protein. To
determine HMGB1simulated platelet secretion, we first
measured the release of ATP in the supernatant in
HMGB1 stimulated WPs (Fig. 4a). The results indicated
that a few micrograms of HMGB1 alone was suficient
to induce platelets release of ATP, when WPs incubated
with HMGB1 protein (1 μg/ml), measured ATP in
the supernatant were 0.70 ± 0.08 nmol/mL, while the
Fig. 3 HMGB1 enhanced agonists-induced platelet aggregation. a A subthreshold concentration of thrombin (0.2 U/ml) or collagen (0.3 μg/ml)
was added to WPs which were preincubeted with HMGB1 (1 μg/ml) or ALB for 10 min at 37 °C, above is representive platelet aggregation
curve. b Data are expressed as mean ± SE, HMGB1 (1 μg/ml) that significantly enhancing thrombin or collagen-induced platelet aggregation
rate (n = 5, *P < 0.05. vs collagen + ALB or thrombin + ALB group respectively). c Representative map of thromboelastogram (TEG) analyzes, the
whole blood prior stimulated with HMGB1 (1 μg/ml) for 10 min at 37 °C, this one Maximum Amplitude (MA) was 77.1 mm. d Analyzing quantitative
data from C, the MA of the HMGB1 group were enhanced (n = 5, *P < 0.05. vs HMGB1 + ALB)
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control (add Buffer) were only 0.53 ± 0.07 nmol/ml,
ATP secretion was sinificantly enhanced in HMGB1-
stimulated WPs. Similarly, in order to exclude the
possibility that contaminating LPS contributes to the
observed increase platelet secretion. LPS (500 pg) was
able to slightly increase ATP in WPs (P > 0.05), co-
incubation with PMB (1 μg/ml) completely blocked
LPS-mediated platelet secretion, but did not change
rHMGB1-induced platelet secretion (Fig. 4d).
During platelet activation, P-selectin is translocated
from intracellular granules (α-granules) to the external
membrane, it expression on platelets determines size
and stability of platelet aggregates [22]. HMGB1 indu-
cing platelets P-selectin expression and the results
suggested that HMGB1 also stimulated platelets α
granule secretion (Fig. 4b, c). measured P-selectin ex-
pression level in HMGB1-incubated (1 μg/ml) WPs
were 14.0 % ± 5.3 %, although P-selectin expression
level had a slightly increase while the results between
the two (control group, 6.4 % ± 4.8 %) had no statistical
difference, higher dose of HMGB1 (10 μg/ml) pro-
duced a significant increase P-selectin-positive plate-
lets. in a words, these results revealed that HMGB1
stimulate platelet both dense and α granule.secretion.
Fig. 4 a ATP release was determined (by ATP Assay Kit) in rHMGB1-incubated WPs (1 × 109/ml), WPs were treated with rHMGB1 (1-80 μg/ml) in
an aggregometer (1200 rpm) for 5 min at 37 °C (n = 6, *P < 0.05 vs. rest group). b WPs were pre-incubated with various concentrations of HMGB1
protein for 10 min, fixed with paraformaldehyde, then incubated with HMGB1 in the presence of a monoclonal anti-human P-selectin Ab or
control mouse IgG (Rest) for 30 min at room temperature. (n = 6, *P > 0.05; **P < 0.05, vs. rest group). c Flow cytometric determination of P-selectin
expression level. d The effects of LPS and PMB on rHMGB1-induced ATP in WPs. (n = 6, *P > 0.05; **P < 0.05, vs. rest group)
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HMGB1-induced platelet aggregation depends on
GPIIb-IIIa complex activation
The linking of the platelets via fibrinogen brings about
platelet aggregation. The glycoprotein (GP) layer of the
platelet, such as GPIb, GPIIb-IIIa or GPIa-IIa and so on,
plays a very important role in platelet function including
adhesion and aggregation [23]. Normal primary platelet
aggregation mainly requires agonist-mediated activation
of membrane GPIIb-IIIa, which directly interact with
fibrinogen mediated platelet-platelet interactions, may
be involving other GP. We unknown whether HMGB1-
induced platelet aggregation also mediated via GPIIb-
IIIa which triggered an outside-in signaling cascade. Next,
we found a patients with Glanzmann thrombasthenia
(GT), who was first diagnosed and molecular biological
analyses showed a severe reduction in surface GPIIb-IIIa
receptors in platelets [20]. (Figure 5a) (the details of
diagnosis information we published in Blood, 1996). The
most common of GT patients, was characterized by a
defective platelet aggregation in response to agonists that
depended GPIIb-IIIa receptors. results from we found
that HMGB1 was incapable of inducing platelet aggrega-
tion in patients with GT, as positive control, ristocetin
can stimulate GT patients platelet aggregation via charac-
terizing the interaction of von Willebrand factor (VWF)
with platelets GPIb [24]. Furthermore, to obtain more
direct evidence for such a linkage that the activated
conformation of GPIIb-IIIa formation on HMGB1-
mediated platelets. We confirmed PAC-1 expression on
HMGB1-stimutited platelets by flow cytometry. The
results indicated that a significant increase of PAC-1
expression on HMGB1-stimulated platelets. All these
results indicated that signaling in HMGB1-induced
platelet aggregation also depending an increased affin-
ity of integrin GP IIb/IIIa.
HMGB1 induced platelet activation depended TLR4
At present, it is very clear that HMGB1 transmembrane
signaling pathways mainly depend TLR-4, TLR-2, and
RAGE [10, 11]. To evaluate the potential roles of these
receptors in HMGB1-induced platelet activation, the
involvement of TLR2, TLR4 and RAGE in HMGB1-
induced platelets aggregation or secretion was investi-
gated by specific neutralising antibodies. WPs were pre-
incubated with various concentration of blocking Abs
directed against these receptor for 20 min respectively
and then rHMGB1 (40 μg/ml) was added to platelet ag-
gregation test. Our results suggested that HMGB1- in-
duced platelet aggregation was obviously decreased after
in the presence of increasing concentrations of anti-
TLR4 Abs. in contrast, the irrelevant control antibody
(IgG2a) or anti-TLR2 Abs and anti-RAGE Abs did not
alter HMGB1-induced platelet aggregation even when
given the same concentrations. Similarily, change in
Fig. 5 HMGB1-induced platelet aggregation depends on GPIIb-IIIa. a the results of the flow cytometric analysis of a patients with Glanzmann
thrombasthenia (GT), CD41a and CD61 only expressed 0.7 % and 0.5 % respectively. b HMGB1 was incapable of promoting platelet aggregation
in patients with GT, as positive control, Ristocetin (1.25 mg/ml) can promote platelet aggregation. c Representative graph of Flow cytometry
analysis of PAC-1. d HMGB1 up-regulated the expression of platelet surface Pac-1 (n = 5, *P < 0.01 vs. ALB)
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expression of P-selectin was consistent with above ob-
servations. WPs pretreatmented with anti-TLR4 (50 μg/
mL) for 20 min and then HMGB1 (40 μg/mL) was
added to measure P-selectin expression, the exposure of
P-selectin were reduced from 52.8 % ± 5.6 % to 24.7 % ±
6.1 % in HMGB1-simulated WPs (*P < 0.05) (Fig. 6f, g),
meanwhile, we examined the effect of the simultaneous
with all neutralizing antibodies and the results indicated
incapable of any further enhance the inhibition effect
(data not shown). In conclution, above results suggested
that the stimulatory effect of HMGB1 on platelet activa-
tion is, at least in part, TLR4 dependent.
Fig. 6 HMGB-induced platelet activation dependent on TLR4, the data shown here are representatives of at five experiments from different donors.
Results are Means ± SD. Prior to stimulation with HMGB1 (40 μg/ml), WPs were pretreatmented with various conceration of anti-TLR4 Abs, anti-TLR2
Abs, anti-RAGE Abs, or irrelevant control concerationg IgG2a in an aggregometer (1200 rpm) for 20 min respectively. Representative aggregation curves
with anti-TLR4 (a), anti-TLR2 (b), anti-RAGE (c) or IgG2a (d) are shown. e, f Statistical analysis of the maximum platelet aggregation rata
(n = 5, *P < 0.05, **P < 0.01, vs IgG2a) and P-selectin expression data (n = 5, *P < 0.05 vs IgG2a). g Representative flow cytometric data
showed that reduced HMGB1-induced P-selectin expression
Yang et al. Diagnostic Pathology  (2015) 10:134 Page 9 of 14
HMGB1 stimulates platelet aggregation by blocking the
activity of nitric oxide/cGMP signaling
cAMP and cGMP were an important secondary messen-
ger in platelet, cAMP-dependent protein kinase A and
cGMP-dependent protein kinase substrates translate
prostacyclin and nitric oxide signals into a block of
platelet adhesion, granule release, and aggregation [25]
to investigated intracellular cAMP and cGMP levels in
HMGB1-stimulated WPs by immunoassay kit, we mea-
sured cAMP and cGMP level in HMGB1-stimulated
WPs and interesting found cGMP levels decreased in a
dose-dependent manner after presence of serum, how-
ever, the changed of cAMP levels had no statistical
difference (Fig. 7a). The reduced of cGMP levels play
what a role in HMGB1-stimulated platelet was unknow,
so next, we prior adding cGMP analogs 8-pCPT-cGMP
or cGMP-elevating NO donor SNP WPs (sodium nitro-
prusside) to WPs respectively. The result indicated that
HMGB1 (40 μg/ml)- induced the maximum platelet
aggregation rate was significantly reduced after platelets
incubation with 8-pCPT-cGMP, or SNP (ALB used as a
negative control) (Fig. 7b, c). Above results suggested
that nitric oxide/cGMP signaling play a suppressing role
in HMGB1-stimulated platelets activation. On the other
hand, we previous studies indicated that HMGB1 signals
by binding to TLR4 to induce platelets activation, to
investigate whether TLR4, TLR2 and RAGE receptors
may be upstream of the cGMP signaling pathway. We ex-
amined the effect of anti-TLR4 Abs, anti-TLR2 Abs and
anti-RAGE Abs on HMGB1-induced cGMP production
respectively, our studies revealed that HMGB1-induced
cGMP level change was almost completely abolished by
anti-TLR4 Abs, there were also slightly inhibited by anti-
TLR2 and anti-RAGE, but both of them have no statis-
tical differences (Fig. 7d). Together with previous found
showed that HMGB1 induced human platelets activation
main depending on TLR4 /cGMP axis and the results
futher supported our previous discover.
Fig. 7 cGMP levels decreased in HMGB1-induced WPs (a) WPs (108/ml) under high shear (1200 rpm) in an aggregometer and stimulated with
HMGB1, 37 °C 10 min, cGMP and cAMP concentrations were determined by using a immunoassay kit (*P < 0.01, **P > 0.05 vs control). b, c WPs
were pretreatmented with 8-pCPT-cGMP (200 μM), or SNP (100 μM) in an aggregometer (1200 rpm) at 37 °C for 10 min and then addition of
HMGB1 (40 μg/mL), platelet aggregation generation was then evaluated (n = 5, *P < 0.05 vs ALB). d WPs were preincubated with mouse IgG2a or
anti-TLR4, anti-TLR2 mAbs or anti-RAGE mAbs (50 μg/ml) at 37 °C for 10 min and then incubated with HMGB1 (40 μg/mL) for 10 min. cGMP level
was evaluated (n = 5, *P < 0.05 vs IgG2a). Results are the Means ± SD of at least 5 experiments
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NF-κB inhibitors impair HMGB1-induced platelet
activation responses
NF-κB is a major transcriptional regulator of genes
involved in survival, proliferation and inflammation of
cell. HMGB1 itself may signal through TLR4 and TLR2,
and via RAGE activation of these receptors results in the
activation of NF-κB, which involved in regulation of
inflammation and activation of immune cells [11], to
evaluated the role of NF-κB in HMGB1-induced platelet
activation. WPs preincubated with various conceration
of NF-κB inhibitors BAY 11-7082 before presented of
HMGB1. the results suggested that HMGB1 mediated
maxim aggregation rate in WPs was markedly inhibited
by BAY 11-7082 in a dose-dependent manner (Fig. 8a).
It was meaning that NF-κB activation playing a stimu-
latory role in HMGB1-induced platelets activation. Fur-
thermore, Fig. 8b shows that HMGB1- induced WPs
activation resulted in IκBα phosphorylation and more
than a 70 % degradation of IκBα (Fig. 2b). both events
were prevented by platelets preincubation the with BAY
Fig. 8 NF-κB inhibitors impair HMGB1-induced platelet activation responses and elevated cGMP level. a, b NF-κB inhibitors impair platelet
aggregation induced by HMGB1, WPs were treated with the indicated concentrations of BAY11-7082 in an aggregometer (1200 rpm) at 37 °C for
5 min and then stimulated with HMGB1 (n = 5, *P < 0.01 vs ALB). c HMGB1 induce IκBα phosphorylation and degradation, WPs were treated with
various dose of HMGB1 for 5 min 37 °C, then Lysates were immunoblotted with an anti- IκBα Ab. d WPs preincubation with BAY 11-7082 under
high shear (1200 rpm) in an aggregometer for 5 min and then stimulated with HMGB1 (40 μg/ml) for 5 min, HMGB1 induce IκBα phosphorylation
can be blocked by BAY 11-7082. (n = 4, P < 0.01 vs control). e Effects BAY 11-7082 on HMGB1-induced cAMP and cGMP, WPs pretreatment with
BAY11-7082 in an aggregometer and stimulated with HMGB1 (40 μg/ml) for 5 min before termination of the reaction and then cAMP and cGMP
enzyme immunoassays were performed. BAY11-7082 significantly increased cGMP accumulation in a dose dependent manner. (n = 4, *P < 0.01 vs.
control). f Effects of a-TLR4, SNP, BAY 11-7082 or ODQ on HMGB1-induced IκBα phosphorylation. WPs were stirred in an aggregometer with
above materials for 5 min prior to the addition of HMGB1 (40 μg/ml). a-TLR4 (50 μg/ml), SNP (100 μM) ODQ (20 μM) and BAY 11-7082 (40 μM),
measured IκBα phosphorylation level, all immunoblots are representative of 3 to 4 similar experiments
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11-7082, a specific inhibitor of NF-κB activation that
prevents IκBα phosphorylation [26] meanwhile, it was
interesting discovered that the cGMP level significantly
elevate in WPs that pre-treatmented with increasing
conceration of BAY11-7082 before adding HMGB1.
(Fig. 8c, d) in order to support above results, we esti-
mated the levels of PAC-1 expression by flow cytometry,
HMGB1-mediated PAC-1 expression were significantly
decreased in BAY 11-7082-treated platelets (data not
show), In addition, we futher confirmed the TLR4/NF-
κB signal passway and show that anti-TLR4 similar to
BAY 11-7082 also showed a similar inhibitory activity
against IκBα phosphorylation.however, guanylate cyclase
(sGC) inhibitor ODQ can increase IκBα phosphorylation
that impaired by BAY 11-7082 in HMGB1 stimulated
platelets (Fig. 8f ). Together, these observations suggest
that TLR4/ NF-κB axis is involved in the regulation of
“inside out” signal depending cGMP signal during in
HMGB1-stimulated platelet activation.
Discussion
Emerging evidence has suggested a potential role for
extracellular role of HMGB1, which was identified as a
proinflammatory cytokine and a late mediator of sepsis.
Beijnum et al first discovered that extracellular HMGB1
levels were elevated in human atherosclerotic plaques,
but not in normal arteries [26]. Then, many studies
demonstrated massive accumulation of HMGB1 in the
systemic circulation would promote the development of
DIC [21, 27] next, our research group first confirmed
that HMGB1 elevated human vascular endothelial cell
tissue factor expression and may be involved in the
pathophysiology of atherothrombosis [12]. Recently an-
other a clinical validation studies showed that a pa-
thogenic relationship between extracellular HMGB1 and
thrombosis has been proposed that circulating concen-
tration of HMGB1 on admission may be a potential and
independent predictor of cardiovascular mortality [13].
Here, our study shows for the first time that HMGB1
induced human platelets aggregation and secretion in a
concentration-dependent manner. Furthermore, HMGB1
stimulates platelet secretion or aggregation mainly, at least
in part, via the TLR4 dependent mechanisms. As men-
tioned above, extracellular HMGB1 is known to interact
with three cell surface receptors: TLR4, TLR2, and RAGE.
Known endogenous ligands released from damaged tis-
sues such as heat-shock proteins [28], histone [17], and
extracellular matrix fragments [29] all interact with TLR2
or TLR4, there is also considerable emerging evidence
demonstrating that TLR4, may play a critical role in
inflammation and autoimmunity, are predominantly in-
volved HMGB1-mediated activation of innate immune
cells [10]. For instance, TLR4 involved in regulation of
HMGB1-induced neutrophil extracellular trap formation
[30] or HMGB1-mediated platelet-tumour cell interaction
[31]. Meanwhile, platelet expression of Toll-like receptor
that was regarded as the link between “danger” ligands
and inflammation [32]. Particularly, platelets depended
express functional TLR4, which is MyD88-dependent or
MyD88- independent pathways, plays a major role in
platelet adhesion and promoting pro-inflammatory cyto-
kine production [33]. Our experimental data suggested
that HMGB1 interact with platelets via TLR4 and then
triggered inside-out signaling in platelets, the conclusion
are supported by our data that when anti-TLR4 mAbs,
anti-TLR2 mAbs and anti-RAGE mAbs are all presenting
in platelets only the HMGB1-stimulated effect is sup-
pressed by anti-TLR4.
In addition, our data suggested HMGB1 signaling were
transmitted from TLR4 to GPIIb/IIIa and then triggers
close cell-to-cell contact between platelets. The intricate
molecular mechanisms underlying regulation of platelet
aggregation are complex. Glycoprotein layer of the platelet
plays a very crucial role in platelet adhesion and aggrega-
tion, the various receptor-specific platelet activation sig-
naling pathways converge into common signaling events
that stimulate platelet shape change and granule secretion
and ultimately induce the “inside-out” signaling process
leading to activation of GPIIb/IIIa, then it trigger “out-
side-in” signaling and acts as a receptor for fibrinogen,
von willebrand factor, and fibronectin, resulting in platelet
granule secretion, stabilization of platelet adhesion and ag-
gregation [34].
Another interesting finding of this study was that the ef-
fect HMGB1 on platelet activation depended the the cGMP
signaling pathway. The conclusion is supported by our data
that HMGB1decrease cGMP level and the effect of platelet
aggregation was abolished by cGMP analogs 8-pCPT-
Fig. 9 HMGB1 involves in platelets signal pathway
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cGMP or cGMP-elevating NO donor SNP which inhibiting
platelet activation. At present, regulation of platelets GPIIb-
IIIa-integrin activation involving dependent or independent
of the NO/cGMP pathway [35]. Most of studtes confirm
the concept that the NO/sGC/cGMP/PKG pathway plays
excluvely inhibitory roles in platelets [25, 36], however, its
effector cGMP also exerts some stimulatory effects on the
early phases of activation [37]. The exact mechanisms
involved in cGMP-mediated platelet inhibition and the
wiring of the cyclic nucleotide signaling network are only
partly understood [25]. cGMP production in platelets de-
pends on a single enzyme, the soluble NO-sensitive guany-
lyl cyclase (sGC or NO-GC), a number of recent studies
about cGMP with platelets have demonstrated that stimula-
tion platelet aggregation by blocking the activity of nitric
oxide/cGMP signaling or elevating cGMP in the inhibition
of platelet aggregation, such as thrombospondin-1 from
platelet-granules inhibits cGMP-mediated activation of
cGMP-dependent protein kinase induced platelet aggrega-
tion [38], activators of cGMP or cAMP inhibition of
collagen-induced platelet aggregation [39].
In addition, previous disccussion that there is a com-
mon regulatory network of inflammation and throm-
bosis, many studies suggested that HMGB1 play a wide
range of biological effects via NF-κB passway, Involving
regulation of inflammation, tumor, immune cells’ activa-
tion [6, 7, 40], meanwhile, although platelets are anu-
cleated cells, NF-κB is expressed in platelets and that
platelet stimulation with agonist triggering IκBα npho-
sphorylation/degradation, importantly, NF-κB inhibitors
are capable of negatively regulating ADP, epinephrine and
collagen induced platelet aggregation [41]. Moreover,
these also studies suggested that NF-kappa B inhibition of
platelet activation dependent the pivotal mechanisms of
endothelial nitric oxide synthase/cyclic GMP [42], the
mechanism is not very clear about NF-kappa B inhibitors
interfere with platelet function.our results indicated NF-
kappa B through cGMP signal regulation of HMGB1
induced activation (Fig. 9). The support data is that gua-
nylate cyclase (sGC) inhibitor ODQ can increase IκBα
phosphorylation that impaired by BAY 11-7082.
Conclusion
In conclusion, our data indicated that rHMGB1-induced
platelet aggregation and secretion via TLR4 receptors,
NF-kappa B, and cGMP depended activation of the
GPIIb/IIIa pathway. Together, these experimental data
provide evidence for the hypothesis that HMGB1 stimu-
lated platelet activation might play an important role in
the haemostasis and thrombotic diseases. This project
might provide a new avenue for the treatment of throm-
botic diseases via blocking HMGB1 or it’s signal passway
in the future.
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